Rheum Cat Profile picture
Nov 11 11 tweets 6 min read
🌟Abs 0001 Botson, et al.
MIRROR RCT: adding MTX to pegloticase for gout
👉52 wk results: response 60% vs 31% pbo

*response: SU<6mg/dl for >=80% of wks 48-52
#ACR22
Abs 0001 cont'd

👉Also: complete tophi resolution 54% MTX vs 31% pbo at 52 wks

#ACR22
🌟Abs 0003 Maher, et al.
RECITAL RCT: RTX vs CYC for CTD-ILD

👉1* outcome change FVC at 24wks - greatest benefit IIM, MCTD
SSc-ILD: ↔ but not improved

#ACR22
🌟Abs 0004 Mandal, et al @ucsf_rheum
Rheumatology Access Expansion Initiative 👉 Improving RA care in Navajo Nation through PCP education
=12wk training program for PCPs including weekly webinars

Surveys to test knowledge, confidence: 👉demonstrates feasibility, impact

#ACR22
🌟Abs 1115 Silva, et al.
Medication copay modifies tx adherence in pts w SLE
🤔Rationale: copays as barrier to SLE tx adherence

Database: Optum
SLE on HCQ, AZA, MMF

#ACR22
Abs 1115 cont'd

Exposure: copay (high vs low)
Outcome: med adherence (PDC >80%)

Sig associations for each med

👉High med co-pays ➡⬇med adherence in SLE

#ACR22
🌟Abs 1116 Jeffries, et al.
Peripheral blood DNA methylation-based #ML models for knee #OA progression prediction

💻Datasets: FNIH OA Biomarkers Consortion subcohort of OAI & JoCo (validation)

#ACR22
Abs 1116 cont'd

KOA progression defined by: 1) radiography, 2) pain, 3) radiography + pain

👉Based on DNA methylation patterns identified as key predictors, infer that pain & structural progression share similar systemic immune epigenotypes
#ACR22
🌟Abs 1675 Messier, et al.
WE-CAN pragmatic RCT: diet + exercise in individuals with knee OA & overweight/obese BMI

👉Treatment effect seen in prior trials in more ideal settings; this study shows that it works in a community-based setting too

#ACR22
🌟Abs 1678 @TonyMerriman2
GWAS revealing new pathogenic pathways in #gout

👉In addition to known pathways (urate regulation, NLRP3 inflammasome and IL-1), CHIP pathway, insulin signalling pathway identified

#goutology #gouterati
#ACR22

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Rheum Cat

Rheum Cat Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @rheum_cat

Nov 13
#ACR22 social media talk, very meta Image
Part 1️⃣: optimize your conference tweeting
If you're reading this you probably know all of this!

The first pro-tip was figure out the conference hashtag
The second? Engage with others in rheum
#ACR22 Image
What else?

👉amplify your group
👉amplify speakers and sessions of interest
👉amplify your colleagues so they will amplify you in turn

#ACR22
Read 10 tweets
Nov 13
#ACR22 infection (COVID) posters Image
Abs 0784 @CCalabreseDO

Cleveland Clinic breakthrough infections, including data on n=21 who received Evusheld

📌Publication here: pubmed.ncbi.nlm.nih.gov/35791921/

#ACR22
@CCalabreseDO Abs 0779 @CCalabreseDO

Experience with evusheld PrEP with IMID on BCDT at Cleveland Clinic

📌Publication here: pubmed.ncbi.nlm.nih.gov/36123015/

#ACR22
Read 13 tweets
Nov 13
The EULAR e posters were tiny (bad) but speakers could zoom in and out (good)

That would have been nice for #IgniteTalks #ACR22
The sound is adequate though. EULAR issue was that the sound was poor in their (smaller) poster tour stages #ACR22 #IgniteTalk
Read 4 tweets
Nov 13
#ACR22 epidemiology posters Image
Abs 0700 @zach_wallace_md
💻Using NLP, ML algorithms to identify ANCA vasculitis cases

They also looked at the difference in performance metrics with/without filtering keywords

An explosion of NLP studies in rheum! #ACR22
@zach_wallace_md Abs 0732 Ho, et al. @JYazdanyMD @MilenaGianfran
💻Part of the explosion of NLP studies in rheum

Here the UCSF group aimed to capture VZV cases (differentiate from vaccination); and to capture active vs historical cases

See their diagrams explaining the steps!
#ACR22
Read 13 tweets
Nov 13
We have learned quite quickly that a virtual ONLY poster hall mixed into a hybrid meeting doesn't work well.

Poor wifi and the crashing platform compound the problem

And if it's online ONLY, is that truly hybrid?

#ACR22
This is not a complaint thread. I am hoping we can have discussion about what works/doesn't work, and what could be done next year for #ACR23
It goes without saying that an in-person poster hall is the most requested item on the wishlist for #ACR23

@GrantSchulert @Tuhina_Neogi
Read 5 tweets
Nov 13
Biostatician @MikeLaValley8 @BU_BMC_Rheum presents a quick overview on how to appropriately interpret results from studies #ACR22

Of course this is not an exhaustive deep dive, but covers some common errors of interpretation Image
@MikeLaValley8 @BU_BMC_Rheum First, what is your research question? What is the question you are trying to answer with t he study?

👉Does this exposure CAUSE this outcome?

#ACR22 Image
@MikeLaValley8 @BU_BMC_Rheum What are common observational study designs and what are big issues to watch out for?

These are issues that can affect the validity of their results.

There are more potential issues within these study designs that is beyond the scope of this table

#ACR22 Image
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(